Clinical and transcriptomic characterization of mixed granulocytic phenotype in chronic obstructive pulmonary disease.
J Allergy Clin ImmunolJun 30, 2026 (epub)
Clinical ResearchPulmonology
Clarus Leung, Jung-Wan Yoo, Hye Yun Park et al.
✦ AI-curated · Sources linked
In 30 seconds
This post hoc analysis of the DISARM randomized controlled trial examined mixed granulocytic COPD in 54 patients, defined by eosinophils >1% and neutrophils >3% in bronchoalveolar lavage. The study found that 33% of patients had this phenotype, which was associated with the lowest FEV1, highest annualized exacerbation rates, and significant immune response and tissue remodeling gene expression.
Key findings
- 33% of patients had mixed granulocytic COPD.
- Patients with this phenotype had the lowest FEV1 and highest annualized exacerbation rates.
- Mixed granulocytic COPD showed increased expression of immune response genes compared to other phenotypes.
- This phenotype was associated with significant tissue remodeling processes.
Why it matters
Understanding the distinct characteristics of mixed granulocytic COPD can help clinicians identify patients at higher risk for severe outcomes, potentially guiding more tailored management strategies.